



**ANNUAL REPORT**  
**2020 - 21**



3B BlackBio Biotech India Ltd.



NOTICE OF ANNUAL GENERAL MEETING

NOTICE is hereby given that the ANNUAL GENERAL MEETING of M/s 3B BLACKBIO BIOTECH INDIA LIMITED, will be held at the Registered office of the Company at 7-C, Industrial Area, Govindpura, Bhopal 462023 on Wednesday, the 22<sup>nd</sup> September, 2021 at 1:30 P.M. to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31<sup>st</sup> March, 2021 together with the Reports of Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Dharendra Dubey, (DIN: 01493040), Wholetime Director, who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint auditors and fix their remuneration for the year ending on 31<sup>st</sup> March, 2021.
4. To approve final dividend of 100%, on equity shares for the financial year 2020-21.

**BY ORDER OF THE BOARD OF DIRECTORS**



**DHIRENDRA DUBEY**  
**CHAIRMAN & DIRECTOR**  
**DIN: 01493040**

**Place: Bhopal**  
**Dated: 23-06-2021**

**Registered Office:**  
**7-C, Industrial Area,**  
**Govindpura, Bhopal-462 023.**  
**CIN: U24232MP2010PTC024717**  
**Ph: 91-755-4077847**  
**Fax: 91-755-2580438 Website: www.3bblackbio.com**  
**Email: info@3bblackbio.com**

**Notes:**

1. An explanatory statement pursuant to section 102 of the Companies act, 2013 setting out all material facts is annexed hereto.
2. A member entitled to attend and vote at the meeting is entitled to appoint another person as his proxy to attend and vote instead of himself/herself and a proxy need not be a member of the Company.
3. The instrument appointing the proxy should however, be deposited at the Registered Office of the Company not less than forty – eight hours before the commencement of the meeting.
4. Members who require more information about the accounts are requested to inform the Company 7days in advances their intention to do so, that the proper records relating thereto may be made available.
5. Members are requested to produce the attendance slip duly signed.

DETAILS UNDER SS-2 OF SECRETARIAL STANDARDS ON GENERAL MEETING REGARDING APPOINTMENT OR RE-APPOINTMENT OF THE DIRECTORS

Name of the Director	<b>Mr. Dharendra Dubey</b>
Category	Executive, Promoter
Date of Birth	29/04/1967
Date of First Appointment	12/11/2010
Qualifications	B.Sc.
Brief Profile and Expertise in Specific functional Area	Mr. Dharendra Dubey aged 54 years is Whole Time Director of the Company, is an entrepreneur. He is looking after the Marketing, R&D, Administration and procurement. He has been associated with the Company since 2010 as Promoter Director. Spanning 30 year's experience, Shri Dharendra Dubey has hands -on wide experience in Biotechnology & Molecular Diagnostic industry in Marketing, R&D & day-to-day business running. Shri Dharendra Dubey devotes whole time attention to the management of the commercial affairs of the company. He is responsible for the day-to-day administration of the company and carries out his duties as entrusted to him from time to time by the Board of Directors.
List of other Directorships held in Public Limited Companies	Kilpest India Limited, Holding Company
Chairman/ Member of committees of the Board of Companies of which he is a director	Nil
Shareholding as on 31-03-2021	40000 equity shares
Number of Meeting of Board attended during the year and other directorship etc.	9 in M/s 3B BLACKBIO BIOTECH INDIA LIMITED, SUBSIDIARY COMPANY. 9 in M/s KILPEST INDIA LIMITED, HOLDING COMPANY.
Membership, Chairman of Committees in the Outside Companies	Nil
Remuneration last drawn	Rs. 18.00 Lacs Per Annum + Commission of 1.5% of net profit
Relationship with other Directors/KMP etc.	Brother of Mr. Nikhil Kuber Dubey, Whole-Time Director

**3B BlackBio Biotech India Limited**  
**CIN : U24232MP2010PTC024717**

The company along with its US associate Genophyll LLC, undertook the huge task of getting its TRUPCR® SARS CoV-2 RT qPCR Kit approved by US-FDA, US-FDA (EUA) was granted on June 19, 2020.

With this, 3B BlackBio Biotech India Ltd. became first ever Indian molecular diagnostics company to receive US FDA-(EUA). Especially at times when more and more reliable testing is the need of the hour for India as well as other countries, TRUPCR® will be a reliable option for labs across the globe to perform the molecular testing for Covid-19 suspected individuals. TRUPCR®SARS CoV-2 V.2 RT qPCR Kits with its unique design of screening and confirmatory assays which detects three genes from the SARS-CoV-2 virus with Endogenous Control gene (RNase P) Internal control for each sample to minimize false negative results. With Grant of US FDA-(EUA), we would be able to expand our customer base globally, and we would emerge as one of the most reliable RT qPCR kits suppliers from India. Ensuring success to "MAKE IN INDIA" vision of Hon'ble Prime Minister.

3B BlackBio Biotech India Limited was established in 2010 with the vision of indigenously developing "Molecular Diagnostic tests" which are developed and validated to International standards & Reference material. Being an import substitution product it helps country save precious foreign exchange and builds confidence in the medical fraternity for Indian products. 3B BlackBio Biotech India Limited is already the first company to have launched India's first home made test for last virus pandemic of H1N1, commonly known as Swine Flu. In fact, till now, 3B BlackBio Biotech is the only company to have developed the swine flu test based on National (NCDC) & International guidelines, validated by NIV Pune and is CDSCO certified.

Acknowledging the efforts of 3B BlackBio, on May 11 2018, Hon'ble President of India, Shri Ram Nath Kovind gave national award to 3B BlackBio for commercializing indigenous technologies. In the event, 3B BlackBio Biotech India Limited, had been declared as the winner of National Award 2018 under MSME category for the successful commercialization of a technology based product- "TRUPCR® BCR ABL1 Quantitative Kit" for detection of BCR-ABL1 fusion gene in patients suffering with Chronic Myeloid Leukaemia (CML) & monitor response to drug therapy, on WHO international standards.

The company has made great achievements in terms of sales & profits, the molecular diagnostic business shall continue to grow well for few years from now; with new product addition (with continuous R & D efforts), new customer addition, and venturing into export markets.

Your Company's products command a very good brand image in the market, and the company is regarded by big labs as a reliable solution provider at par to the foreign multinational.

It has made a wide range of diagnostic kits ranging from infectious diseases to \*oncology, which are being accepted by big names customers in diagnostic market. The company has become a market leader in India. Company's (Molecular Diagnostic Business) sales grew by 1294.36% from Rs 1536.29 lacs to Rs 21421.35 lacs and EBITDA grew from Rs 975.86 lacs to Rs 15036.71 lacs; PAT grew from Rs 707.34 lacs to Rs 11215.08 lacs

**DIRECTORS' REPORT**

Dear Members,

Your Directors have pleasure in presenting the Eleven Annual Report on the business and operations of your Company along with the Audited Financial Statements, for the Financial Year ended March 31, 2021.

**1. FINANCIAL RESULTS:**

The Company's financial performance for the year ended 31<sup>st</sup> March 2021 is summarized below:

Particulars	(Rs. in Lacs)	
	For the year ended 31 March, 2021	For the year ended 31 March, 2020
Total Revenue	21705.61	1577.81
Less: Expenditure	6668.89	602.44
Less: Depreciation	41.53	32.09
Add: Exceptional item	0.00	0.50
Profit/(loss)before Tax (PBT)	14995.18	943.78
Less: Tax Expense		
1. Current Tax	3742.06	235.66
2. Deferred Tax	31.28	4.61
3. Previous year Income Tax	6.76	5.38
	11215.08	707.34

**2. INDUSTRY POTENTIAL- MOLECULAR DIAGNOSTICS**

The current market size for next generation diagnostics (including molecular diagnostics) in India between Rs. 700 – Rs. 800 crores and growing around 15%.

**3. PERFORMANCE FOR THE YEAR 2020-21 :**

On April 02, 2020, 3B BlackBio Biotech India Limited , developed Real-Time PCR Detection Kit for SARS CoV-2 (COVID-19). The kit has been given ICMR approval for use on patient samples. TRUPCR® SARS CoV-2 Real-Time PCR test is a molecular detection test which screens and detects COVID-19 specific genes and is a confirmatory test.

It works on any of the Real-Time PCR instrument available with the labs and hence it does not require any new expense on new or closed systems. The test comes with robust internal control in all testing tubes making it one of the most reliable tests currently available in the market.

**4. SHARE CAPITAL**

The paid up Equity Share Capital stood at Rs 1, 02, 75,000/- on 31st March, 2021. During the year under review, the Company has not issued any shares. The Company has not issued shares with differential voting rights. It has neither issued employee stock options nor sweat equity shares and does not have any scheme to fund its employees to purchase the shares of the Company.

**5. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND**

As per the provisions of Section 125(2) of the Companies Act, 2013, no unpaid dividend was required to be transferred to the Investor Education and Protection Fund during the year.

**6. CORPORATE SOCIAL RESPONSIBILITY:**

Your Company has constituted an independent Corporate Social Responsibility Committee pursuant to section 135 of the Companies Act, 2013.

**COMPANY'S PHILOSOPHY:**

The Company's CSR philosophy is based on the belief that a successful business can develop only by creating a prosperous society around. Reaching out to deprived communities is part of the Company's vision and its CSR initiatives aim at supplementing government endeavors' to help the citizens in the vicinity to achieve better living standards and good quality of life. The Company has been engaging with civil society, public at large through dissemination of its CSR initiatives.

**Corporate Social Responsibility Policy:**

The Company has adopted a Corporate Social Responsibility Policy as required under section 135 of the Companies Act, 2013 for the activities covered under Schedule VII of the Act. The CSR Policy may be accessed on the Company's website at the link: [http:// www.3bblackbio.com](http://www.3bblackbio.com)

The Annual Report on CSR activities is annexed herewith marked as **Annexure C**.

**7. DETAILS OF UNCLAIMED DIVIDEND**

In order to help Members ascertain the status of unclaimed dividends, the Company has uploaded the information in respect of unclaimed dividends for the financial year ended 31st March, 2020 as on the date of the previous AGM i.e. 25<sup>th</sup> September, 2020 (10th AGM) on the website of Investor Education and Protection Fund, at [www.iepf.gov.in](http://www.iepf.gov.in) .

**8. PUBLIC DEPOSITS**

The Company has not accepted any deposits from the public during the year under review. No amount on account of principal or interest on deposits from the public was outstanding as on March 31, 2021.

**9. TRANSFER TO RESERVES:**

The balance of Profit and Loss Account after adjusting income tax, interim dividend, final dividend and tax on proposed dividend is proposed to be transferred to Reserves and Surplus.

**10. CHANGES IN THE NATURE OF BUSINESS, IF ANY:**

There was no change in the nature of business of the Company during the financial year ended 31st March 2021. Further there have been no material changes and commitments, if any affecting financial position of the Company from financial year end and till the date of this report.

**11. EXPANSION:**

The Company has taken steps to consolidate the production for achieving the economies of scale. However, the Company has not taken up any major expansion during the year under review.

**12. DIRECTORS**

In accordance with the provisions of the Companies Act, 2013, Mr. Dharendra Dubey, Director retiring by rotation and being eligible, offered himself for re-appointment at the ensuing Annual General Meeting.

Independent Director has given declaration that he meets the criteria of independence as prescribed under the provisions of the Companies Act, 2013 read with schedules and rules. In the opinion of the Board, he fulfills the conditions of independence as specified in the Act and the Rules made thereunder and are independent of the management. There has been no change in the circumstances affecting his status as Independent Director of the Company.

The Board is of the opinion that the Independent Director of the Company possess requisite qualifications, experience and expertise in the fields of science and technology, digitalization, human resources, strategy, auditing, tax and risk advisory services, financial services, corporate governance, etc. and that they hold highest standards of integrity.

Necessary information on the Director (s) seeking appointment/ reappointment has been given in the Notice of the ensuing Annual General Meeting.

**13. AMALGAMATION**

Your board has proposed to amalgamate M/s 3B BLACKBIO BIOTECH INDIA LIMITED, TRANSFEROR COMPANY WITH KILPEST INDIA LIMITED, TRANSFEREE COMPANY. The rationale behind this scheme is that, the Amalgamated Company will have greater efficiency in overall business including economies of scale, cash flow management of the amalgamated entity and unfettered access to cash flow generated by the combined business which can be deployed more efficiently for the purpose of development of businesses of the companies and their growth opportunities, eliminate inter corporate dependencies, minimize the administrative compliances, etc. resulting in maximization of shareholders value.

The Board of Directors of the Transferor Company and the Transferee Company are of the opinion that the amalgamation would motivate employees by providing better opportunities to scale up their performance with a corporate entity having large revenue base, resources, asset base, it would also have a larger net-worth base, and greater borrowing capacity and greater efficiency in overall business which will provide impetus to corporate performance thereby enhancing overall shareholder value.



The same is under process with Regulatory Authorities.

#### RATIONALE FOR AMALGAMATION

- a) The management prime focus is to run and grow the Diagnostic business. Hence, 3B BlackBio is being amalgamated with Kilpest and all assets (land, building and equipment) of Kilpest will be dedicated to diagnostic business.
- b) The Amalgamated company will be grown not only in Molecular Diagnostics, but also in other fields like Rapid Cards (based on Antigen and Antibodies) and other related scalable business verticals.
- c) Kilpest will continue to run as an Independent division for some time till the company finds a suitable buyer for its Agrochemical Division to sell its brands and other intangible assets.
- d) As a result of amalgamation of 3B BlackBio (Diagnostic business) with Kilpest, finally we would have a single company to be renamed as 3B BlackBio Dx Ltd. which will be classified as a Diagnostic company and will have over 90% of revenues from Diagnostics Business. The listed company would be renamed as 3B BlackBio Dx Ltd. in order to solely focus on growth and development of Diagnostic business.
- e) Gradually, all immovable assets including land (2 acres) and factory building would be fully utilized for the growth and expansion of 3B BlackBio Dx Ltd. and Research & Development Activities in the field of Diagnostic business.

#### SWAP RATIO & EFFECTS

- a) Existing Paid up Equity Capital of Kilpest is 75,08,100 (No. of Shares) of Rs. 10/- each
- b) Kilpest is holding 87.44% (8,98,500 shares) in 3B BlackBio's total equity of 10,27,500 shares
- c) Pursuant to the scheme of amalgamation 10,74,570 new fully paid up equity shares of Kilpest will be issued to the remaining shareholders of 3B BlackBio, holding 1,29,000 (12.56%) shares at a SWAP ratio of 8.33 shares of Kilpest for 1 share in 3B BlackBio.
- d) The 8,98,500 shares held by Kilpest in 3B BlackBio will get cancelled as per process of amalgamation.
- e) Expanded Equity Capital of Kilpest (to be renamed as 3B BlackBio Dx Ltd.) will become 85,82,670 Equity shares of Rs. 10/- each (Existing Shares: 75,08,100 shares + New Shares to be allotted: 10,74,570 shares).
- f) As a result of this increased equity, every existing shareholder of Kilpest will become direct owner of the Amalgamated company in a ratio of 0.8748%.
- g) The Listed entity shall be renamed as 3B BlackBio Dx Ltd. so that all the stakeholders of Kilpest will directly share the growth and fruitful journey of "Diagnostic Business".

**14. SECRETARIAL AUDITOR**

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors of the Company had appointed M/s P.K. Rai & Associates, Practicing Company Secretary to undertake the Secretarial Audit of M/s 3B BlackBio Biotech India Limited, material subsidiary of M/s Kilpest India Limited for the year ended 31st March, 2021. The Secretarial Audit Report for the Financial Year ended 31st March, 2020 is annexed as Annexure B and does not contain any qualification, reservation, adverse remark or disclaimer.

**15. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANIES**

The Company does not have any Subsidiary, Joint Venture or Associate Company.

**16. EXTRACT OF ANNUAL RETURN**

The extract of Annual Return in Form No.MGT-9 as required under Section 92 of the Companies Act, 2013 for the financial year ending March 31, 2021 is annexed hereto as Annexure A and forms part of this report.

**17. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS**

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

**18. MEETINGS OF BOARD OF DIRECTORS/ GENERAL BODY MEETING**

During the financial year ended March 31, 2021, nine (9) Board meetings were held. The intervening gap between any two board meetings was within the period prescribed under the Companies Act, 2013.

**19. AUDITORS:**

M/s R.C.Baheti & Co. Chartered Accountants, retire at the ensuing Annual General Meeting and are eligible for reappointment.

**20. AUDITORS' REPORT:**

The Report is given by the Auditors on the financial statements of the Company. There has been no qualification, reservation, adverse remarks or disclaimer given by the Auditors in their Report.

**21. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE**

The Company is committed to provide a safe and conducive work environment to its employees, during the year under review. The Board further states that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

**22. HUMAN MANAGEMENT:**

Our Employees are most valuable assets of the Company. We encourage innovation, meritocracy and the pursuit of Excellence. We have setup a scalable recruitment and human resources management process, which enables us to attract and retain employees. Cordial employee relations were maintained throughout the year in Company. The directors express their appreciation for the contribution made by employees to operations of the Company during the year.

**23. PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED**

There were no loan, guarantees or Investments made by the Company under Section 186 of the Companies Act, 2013 during the year under review and hence the said provision is not applicable.

**24. INTERNAL FINANCIAL CONTROLS**

The Directors have laid down internal financial controls to be followed by the Company for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and the completeness of the accounting records and the timely preparation of reliable financial information. During the year, such controls were tested and no reportable material weakness in the design or operation were observed.

**25. INSURANCE:**

The assets of Company are adequately insured against loss of fire, riot, earthquake, flood etc. and other risks which are considered necessary by the Management.

**26. MATERIAL CHANGES & COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRING AFTER BALANCE SHEET.**

No material changes and commitments affecting the financial position of the company occurred between the ends of this financial year to which these financial statements relate on the date of this report.

**27. DIVIDEND**

The Board of Directors at their meeting held on 23<sup>rd</sup> June, 2021, recommended a Final Dividend of 100% (Rs 10.00 per fully paid-up equity shares of Rs 10/- each), for the financial year ended 31st March, 2021. The dividend payout is subject to approval of members at the ensuing Annual General Meeting.

The Board of Directors have also recommended a interim dividend of 750% (Rs 75.00 per fully paid up equity shares of Rs 10/- each), for the financial year 2021-22, being declared, thus taking a total dividend payout of Rs 85/- per equity share.

## **28. CREDIT RATING OF SECURITIES**

The Company is not required to obtain credit rating of securities and hence no credit rating of securities was obtained by the Company.

## **29. NO DEFAULT**

The company has not defaulted in payment of interest and/or repayment of loans to any of the financial institutions and/or banks during the year under review.

## **30. COMMITTEES**

The Company is not required to constitute Audit Committee or Nomination and Remuneration Committee as the company is a private company.

## **31. BOARD EVALUATION**

Being an unlisted private Company, the formal annual evaluation by the Board of its performance and that of its committees and individual Directors are not mandatory.

## **32. DIRECTORS' RESPONSIBILITY STATEMENT:**

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the Statutory and Secretarial Auditors, including audit of the internal financial controls over financial reporting by the Statutory Auditors and the reviews performed by Management and the relevant Board Committees, including the Audit Committee, the Board is of the opinion that the Company's internal financial controls were adequate and effective during FY 2020-21.

The Statement of the Directors' Responsibility on Annual Accounts of the Company referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013 shall state that –

1. that in preparation of annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. that directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of profits and loss of the Company for that period;
3. that the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding assets of the Company and for preventing and detecting fraud and other irregularities;
4. that the directors had prepared Annual Accounts on a going concern basis; and

**3B BlackBio Biotech India Limited**  
**CIN : U24232MP2010PTC024717**

5. the directors, have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

**33. ACKNOWLEDGEMENT:**

The Directors hereby acknowledge the dedicated and loyal services rendered by the employees of the Company during the year. They would also like to place on record their appreciation for the continued co-operation and support received by the Company during the year from bankers, financial institutions, Government authorities, business partners, shareholders and other stakeholders without whom the overall satisfactory performance would not have been possible.

The Directors deeply regret the losses suffered due to the Covid-19 pandemic and place on record their sincere appreciation to all the front-line workers and those who have gone beyond their duties in battling against the pandemic.

**FOR AND ON BEHALF OF THE BOARD**



  
**DHIRENDRA DUBEY**  
**CHAIRMAN & DIRECTOR**  
**DIN: 01493040**

**Place: Bhopal**  
**Dated: 23-06-2021**

**Annexure -A**  
**FORM NO. MGT 9**  
**EXTRACT OF ANNUAL RETURN**

**As on financial year ended on 31.03.2021**

**Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.**

**I. REGISTRATION & OTHER DETAILS:**

1	CIN	<b>U24232MP2010PTC024717</b>
2	Registration Date	<b>12-11-2010</b>
3	Name of the Company	<b>3B BLACKBIO BIOTECH INDIA LIMITED</b>
4	Category/Sub-category of the Company	<b>Non-Government Company Limited by Shares</b>
5	Address of the Registered office & contact details	<b>7 C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462023 (MP) PH: 0755-4077847 E-mail: info@3bblackbio.com</b>
6	Whether listed company	<b>No (deemed Listed)</b>
7	Name, Address & contact details of the Registrar & Transfer Agent, if any.	<b>Not Applicable</b>

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY** (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% total turnover of the company
1	DIAGNOSTIC KITS/PATHOLOGICAL ENZYME	20299	100%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES**

S. No.	Name And Address of The Company	CIN/GLN	Holding/ Subsidiary/Associate	% of shares held	Applicable Section
1	M/S KILPEST INDIA LIMITED, 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL- 462023	L24211MP1972PLC001131	HOLDING	87.45	2(87)



f) Insurance Companies									
g) FIIs									
h) Foreign Venture Capital Funds									
i) Others (specify)									
<b>Sub-total (B)(1):-</b>	0	0	0	0	0	0	0	0	0
<b>2. Non-Institutions</b>									
a) Bodies Corp.									
i) Indian									
ii) Overseas									
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh									
<b>Prateek Goel</b>	50000	0	50000	4.87	50000	0	50000	4.87	0.00
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh									
c) Others (specify)									
<b>Sub-total (B)(2):-</b>	50000	0	50000	4.87	50000	0	50000	4.87	0.00
<b>Total Public Shareholding (B)=(B)(1)+ (B)(2)</b>	50000	0	50000	4.87	50000	0	50000	4.87	0.00
<b>C. Shares held by Custodian for GDRs &amp; ADRs</b>	0	0	0	0	0	0	0	0	0
<b>Grand Total (A+B+C)</b>	998500	29000	1027500	100	998500	29000	1027500	100	0

ii) Shareholding of Promoter-

S No.	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	M/S KILPEST INDIA LIMITED*	898500	87.45	0	898500	87.45	0	0.00
2	M/S 2B BLACKBIO, S.L. SPAIN	29000	2.82	0	29000	2.82	0	0.00
3	Mr. DHIRENDRA DUBEY	40000	3.89	0	40000	3.89	0	0.00
4	MR. NIKHIL KUBER DUBEY	10000	0.97	0	10000	0.97	0	0.00
	Total	977500	95.13	0	977500	95.13	0	0.00



iii) Change in Promoters' Shareholding (please specify, if there is no change)

S No.	Name	Shareholding		Date	Increase/Decrease in share-holding	Reason	Cumulative shareholding during the year (01.04.20 to 31.03.21)	
		No. of Shares at the beginning (01.04.20)/ End of the year (31.03.21)					No. of Shares	% of total shares of the Company
1	M/S Kilpest India Limited*	898500	87.45					
					No movement during the year			
		898500	87.45	31-03-2021				
2	M/S 2B BLACKBIO, S.L. SPAIN	29000	2.82					
					No movement during the year			
		29000	2.82	31-03-2021				
3	MR. DHIRENDRA DUBEY	40000	3.89					
					No movement during the year			
		40000	3.89	31-03-2021				
4	MR. NIKHILKUBER DUBEY	10000	0.97					
					No movement during the year			
		10000	0.97	31-03-2021				

iv ) Shareholding Pattern of top ten Shareholders:  
(Other than Directors, Promoters and Holders of GDRs and ADRs):

S. No.	Name	Shareholding		Date	Increase/Decrease in share-holding	Reason	Cumulative shareholding during the year (01.04.20 to 31.03.21)	
		No. of Shares at the beginning (01.04.20)/ End of the year (31.03.21)	% of total share of the Company				No. of Shares	% of total shares of the Company
1	PRATEEK GOEL	50000	4.87	01/04/2020				
					No movement during the year.			
		50000	4.87	31/03/2021				

v) Shareholding of Directors and Key Managerial Personnel:

S No	Shareholding of each Directors and each Key Managerial Personnel	Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1	<b>Mr. DHIRENDRA KUBER DUBEY, Whole Time Director</b>				
	At the beginning of the year- 01.04.2020	40000	3.89	40000	3.89
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (c.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2021			40000	3.89
2	<b>Mr. NIKHIL KUBER DUBEY, Whole Time Director</b>				
	At the beginning of the year- 01.04.2020	10000	0.97	10000	0.97
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2021			10000	0.97
3	<b>Mr. SHABBAR HUSSAIN, Independent Director</b>				
	At the beginning of the year- 01.04.2020	0	0	0	0
	Date wise increase/decrease in Promoters Share holding during the year specifying the reasons for increase/decrease (e.g. allotment/ transfer/ bonus/ sweat equity etc)	0	0	0	0
	At the end of the year-31.03.2021			0	0

VI. INDEBTEDNESS -Indebtedness of-the Company including interest outstanding/accrued but not due for payment.

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
(Rs in lakhs)				
<b>Indebtedness at the beginning of the financial year</b>				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
<b>Total (i+ii+iii)</b>	0	0	0	0
<b>Change in Indebtedness during the financial year</b>				
* Addition	0	0	0	0
* Reduction	0	0	0	0
<b>Net Change</b>	0	0	0	0
<b>Indebtedness at the end of the financial year</b>				
i) Principal Amount	0	0	0	0
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
<b>Total (i+ii+iii)</b>	0	0	0	0

**VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL- (NIL)**
**A. Remuneration to Managing Director, Whole-time Directors and/or Manager:**

(Rs in lakhs)

S No.	Particulars of Remuneration	Name of MD/WTD/ Manager			Total Amount (Rs.)
		Mr. Dharendra Dubey	Mr. Nikhil Kuber Dubey	-	
1	Gross salary			-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	18.00	18.00	-	36.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission - as % of profit - others, specify...	174.00 -	174.00 -	- -	348.00 -
5	Others, please specify <b>Interest</b>	0	-	-	-
	Total (A)	-	-	-	384.00
	Ceiling as per the Act	10% of Net profit for all Executive Directors- Managing & WholeTime Directors i.e. Rs 1121.00 Lakhs			

**B. Remuneration to other directors (Nil)**

S No.	Particulars of Remuneration	Name of Directors			Total Amount (Rs)
1	Independent Directors	<b>Mr. SHABBAR HUSAIN</b>	-	-	
	Fee for attending board / committee meetings	0	0	0	0
	Commission	-	-	-	
	Others, please specify	-	-	-	
	Total (1)	0	0	0	0
2	Other Non-Executive Directors				
	Fee for attending board / committee meetings	-	-	-	
	Commission	-	-	-	
	Others, please specify	-	-	-	
	Total (2)	0	0	0	0
	Total (B)=(1+2)	0	0	0	0

**C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD (Nil)**

S No.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total (Rs)
1	Gross salary	-	-	-	-
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	-	-	-	-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	-	-	-	-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	-	-	-	-
2	Stock Option	-	-	-	-
3	Sweat Equity	-	-	-	-
4	Commission	-	-	-	-
	- as % of profit	-	-	-	-
	others, specify...	-	-	-	-
5	Others, please specify	-	-	-	-
	Total	-	-	-	-

**VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**


Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
<b>A. COMPANY</b>					
Penalty					
Punishment					
Compounding					
<b>B. DIRECTORS</b>					
Penalty					
Punishment					
Compounding					
<b>C. OTHER OFFICERS IN DEFAULT</b>					
Penalty					
Punishment					
Compounding					

For and on behalf of the Board

Date: 23-06-2021  
Place: Bhopal

  
Nikhil Kuber Dubey  
Director  
(DIN: 00538049)

  
Dhirendra Dubey  
Director  
(DIN: 01493040)



**ANNEXURE-B TO DIRECTORS' REPORT**  
**SECRETARIAL AUDIT REPORT**  
**FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2021**

Pursuant to Section 204(1) of the Companies Act, 2013 and Rule no. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

To,  
The Members,  
**3B BLACKBIO BIOTECH INDIA LIMITED**  
7-C, Industrial Area,  
Govindpura,  
BHOPAL – 462023

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **3B Blackbio Biotech India Limited**, (hereinafter called the "Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2021 according to the provisions of:

1. The Companies Act, 2013 ('the Act') and the rules made there under;
2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
3. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
4. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowing

5. Other Laws applicable to the Company;

- a) The Hazardous Wastes (Management and Handling) Rules 1989;
- b) The Insecticide Act, 1968;
- c) Factories Act, 1948 and Rules made there under
- d) Payment of Bonus Act 1965, & Rules, 1965
- e) Maternity Benefit Act 1961 & Rules
- f) Employees Compensation Act, 1923 & Rules.
- g) Minimum Wages Act, 1948, M.W(C) Rules, 1950
- h) Child Labour (P&R) Act 1986 & Rules.
- i) Air (Prevention and Control of Pollution) Act 1981
- j) Water (Prevention and Control of Pollution) Act 1974
- k) Payment of Wages Act 1936
- l) Employees State Insurance Act 1948
- m) Employees PF & Miscellaneous Provisions Act 1952
- n) Contract Labour (Regulation & Abolition) Act 1970
- o) Medical device Rules, 2017
- p) Industrial Disputes Act, 1947
- q) Indian Contract Act, 1872
- r) Environment Protection Act, 1986 and other environmental laws
- s) Payment of Gratuity Act, 1972
- t) Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act 2013

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

We further report that

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

- Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes. All the decisions have been taken unanimously and no dissent recorded.

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period, there are no specific events / actions having a major bearing on the Company's affairs in pursuance of the laws, rules, regulations, guidelines, standards, etc, referred to above.

**For P.K.Rai & Associates**  
**Practicing Company Secretary**

**CS PRAVEEN KUMAR RAI**  
M. No: 6313  
C. P. No. 3779  
UDIN: F006313C000707035

Date:- 29<sup>th</sup> JULY, 2021  
Place: Bhopal

To,  
The Members,  
**3B BLACKBIO BIOTECH INDIA LIMITED**  
7-C, Industrial Area,  
Govindpura,  
BHOPAL – 462023

**Our Secretarial Audit Report of even date is to be read along with this letter.**

Management's Responsibility

1. It is the responsibility of the management of the company to maintain secretarial records, devise proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor's Responsibility

2. Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the company with respect to secretarial compliances.
3. We believe that audit evidence and information obtained from the Company's management is adequate and appropriate for us to provide a basis for our opinion.
4. Wherever required, we have obtained the management's representation about the compliance of laws, rules and regulations and happening of events etc.

**Disclaimer**

5. The secretarial Audit Report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company

**For P. K. Rai & Associates**  
**Practicing Company Secretary**

**CS PRAVEEN KUMAR RAI**  
M. No: 6313  
C. P. No. 3779  
UDIN: F006313C000707035

Date: - 29<sup>th</sup> JULY, 2021  
Place: Bhopal



## ANNEXURE-C TO DIRECTORS' REPORT

Annual Report on Corporate Social Responsibility (CSR) activities for the Financial Year 2020-21

### 1. Brief outline of Company's CSR Policy:

As a responsible business, 3B BlackBio Biotech India Limited takes pride in being socially inclined and focuses on sustained and effective Corporate Social Responsibility Projects. Today we define Corporate Social Responsibility as the way a Company balances its economic, social and environmental objectives while addressing stakeholder expectations and enhancing shareholders value. Our employees are also encouraged to volunteer their time and skills and enjoy the experience of giving back to the communities in which they work.

The Company has identified the projects in a participatory manner, in consultation with the interested communities and in consonance with Schedule VII of the Companies Act, 2013. Arising from this, the focus areas that have emerged are the Rural and Infrastructure Development, providing quality education, preventive health care, sustainable livelihood and environment sustainability. All of our projects of CSR to be carried by the 3B BlackBio Biotech India Limited or through the Trust/ Society in accordance with the Act and Rules.

Web Link: <https://www.3blackbio.com>

### 2. Composition of CSR Committee:

Sl. No.	Name of Director	Designation/ Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Shabbar Hussain	Chairman/ Independent Director	5	5
2	Dhirendra Dubey	Member/ Whole Time Director	5	5
3	Nikhil Kuber Dubey	Member/ Managing Director	5	5

3. Web Link: <https://www.3blackbio.com/investors.html>

4. Details of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8 of the

Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report): Not Applicable

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year: Nil

6. Average net profit of the Company as per section 135(5): Rs. 663.15 lac

7. (a) Two percent of average net profit of the company for preceding three years as per section 135(5): 13.26 Lacs

(b) Unspent amount of the previous financial year: 3.14 lac

(c) Amount required to be set off for the financial year: Nil

(d) Total CSR obligation for the financial year (7a+7b-7c): 16.40 lac

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per Section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of Transfer	Name of the Fund	Amount	Date of Transfer
16,40,000/-	Nil		Nil		

(b) Details of CSR amount spent against ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project.		Project duration.	Amount allocated for the project (In Rs.)	Amount spent in the current financial year (In Rs.)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (In Rs.)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District						Name	CSR registration Number

1	Rama Krishna Mission Ashrama	Promotion of Education and employment enhancing skills especially among the children	No	West Bengal	Manasadiwip	Two Years	2,00,000	2,00,000	NIL	Yes		Nil
					<b>TOTAL</b>		2,00,000	2,00,000	NIL			

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

(1) Sl. No.	(2) Name of the Project.	(3) Item from the list of activities in Schedule VII to the Act.	(4) Local area (Yes/No).	(5) Location of the project.		(6) Amount spent for the project (Rs).	(7) Mode of implementation - Direct (Yes/No)	(8) Mode of implementation - Through implementing agency.	
				State.	District.			Name.	CSR registration number.
1	Promotion of Education for Books/Library upkeep at Tulsi Manas Prathisthan	Promotion of Education	Yes	Madhya Pradesh	Bhopal	1,25,000/-	Yes	-	-
2	Distribution of Blankets to Homeless during winters/Covid-19	Promotion of Healthcare	Yes	Madhya Pradesh	Bhopal	27,000/-	Yes	-	-

3	Financial Support to Shri Ramakrishna Math, Baranagar for education, food and healthcare of unprivileged children.	Promotion of Education	No	West Bengal	Baranagar	3,15,000/-	Yes	-	-
4	Sight Savers for Rural Eye Health Programme	Health Care	Yes	Madhya Pradesh	Chindwara	2,44,000/-	Yes	-	-
5	Sight Savers for Rural Eye Health programme , ( ongoing project)	Health Care	Yes	Madhya Pradesh	Chindwara	7,32,000/-	Yes	-	-
				<b>TOTAL</b>		<b>14,43,000/-</b>			

(d) Amount spent in Administrative Overheads: Nil

(e) Amount spent on Impact Assessment: Nil

(f) Total amount spent for the Financial Year: 16,43,000/-

(8b+8c+8d+8e)

(g) Excess amount for set off: Nil

Sl. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the company as per Section 135(5)	16,40,000/-
(ii)	Total amount spent for the Financial Year	16,43,000/-
(iii)	Excess amount for the Financial Year[(ii)-(i)]	3,000/-

(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	3,000/-

9. (a) Details of Unspent CSR amount for the preceding three financial years:

Sl. No	Preceding Financial Year.	Amount transferred to Unspent CSR Account under section 135(6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
				Name of the Fund	Amount (in Rs).	Date of transfer.	
-----Not Applicable-----							

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No	Project ID.	Name of the Project.	Financial Year in which the project was commenced.	Project duration.	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting Financial Year (in Rs).	Cumulative amount spent at the end of reporting Financial Year. (in Rs.)	Status of the project - Completed /Ongoing.
-----Not Applicable-----								

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year (asset-wise details):

(a) Date of creation or acquisition of the capital asset(s): **NA**

(b) Amount of CSR spent for creation or acquisition of capital asset: **NA**

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: **NA**

(d) details of the capital asset(s) created or acquired (including complete address and location of the capital asset): **NA**

11. Reasons for failure to spend two per cent of the average net profit as per section 135(5): **NA**

-----



**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

**INDEPENDENT AUDITOR'S REPORT**

To,

The Members of 3B Black Bio Biotech India Limited

**Report on the Financial Statements**

We have audited the accompanying financial statements of 3B Black Bio Biotech India Limited ('the company') which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss, (including Other Comprehensive income), Statement of Changes in Equity, Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

**Basis of Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section, of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the 'ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the financial statements.


**Key Audit Matter**

Key audit matters are those matters that in our professional judgement were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

**Other Information ["Information other than the Financial Statements and Auditor's Report thereon"]**

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the board report but does not include the financial statements and our auditor's report thereon.





**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

**INDEPENDENT AUDITOR'S REPORT**

To,

The Members of 3B Black Bio Biotech India Limited

**Report on the Financial Statements**

We have audited the accompanying financial statements of 3B Black Bio Biotech India Limited ('the company') which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss, (including Other Comprehensive income), Statement of Changes in Equity, Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

**Basis of Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section, of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the 'ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the financial statements.

**Key Audit Matter**

Key audit matters are those matters that in our professional judgement were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the financial statement as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.


**Other Information ["Information other than the Financial Statements and Auditor's Report thereon"]**

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the board report but does not include the financial statements and our auditor's report thereon.









**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Director's are responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibility**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.







**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other







**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**Report on Other Legal and Regulatory Requirements**

- 1) As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 2) As required by section 143 (3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge belief were necessary for the purpose of our audit.
  - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c. The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
  - d. In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under section 133 of the Act.
  - e. On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
  - g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
    - i. The Company does not have any pending litigations which would impact its financial position.
    - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.







**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**


24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

**For R.C. BAHETI & CO.**

Chartered Accountants

Firm's registration No: 403034C

  
Ranjan Baheti

(Partner)

Membership No: 400993

Date: 29/06/2021


Place: Bhopal

UDIN: 21400993AAAADV3550









**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)


**“Annexure A” to the Independent Auditors’ Report**

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the financial statements of the Company for the year ended March 31, 2021:

- 1) In respect of its fixed assets:
  - (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
  - (b) The Fixed Assets have been physically verified by the management at reasonable intervals. In our opinion the frequency of verification is reasonable having regard to the size of the company and nature of the assets. To the best of our knowledge, no material discrepancies have been noticed on such verification.
  - (c) No immovable property held in the name of the company.
- 2) In respect of its Inventories:
  - (a) The inventory of finished goods, raw and packing materials and store and spare parts has been physically verified during the year by the management. In our opinion, the frequency of such verification is reasonable.
  - (b) In our opinion and according to the information and explanations given to us, the procedure for the physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the company and the nature of its business. To the best of our knowledge, no material discrepancies have been noticed on such verification.
  - (c) In our opinion and according to the information and explanation given to us, the Company is maintaining proper records of inventory.
- 3) The company has not granted any loans secured or unsecured to firms or other parties covered in the register maintained under section 189 of the companies Act, 2013.
- 4) The company has not given any loans, investments, guarantees and security. Hence the provisions of section 185 and 186 of the Companies Act, 2013 are not applicable.
- 5) The company has not accepted any fresh deposits during the year.
- 6) As per information and explanations given to us, the Central Government has not prescribed the maintenance of cost records under section 148(1) of the Companies Act, 2013.
- 7) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company is generally regular in depositing undisputed statutory dues including Income-Tax, Duty of Customs, Cess, Goods and Services Tax (GST) and any other statutory dues with the appropriate authorities applicable to it.
- 8) There are no loans or borrowings from Banks, Financial Institutions, Government or dues to Debenture holder, hence this clause is not applicable.







**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

- 9) No term loans availed during the year hence this clause is not applicable.
- 10) In our opinion and according to the information and explanation given to us, that no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- 11) In our opinion and according to the information and explanation given to us, the Company has paid /provided managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act 2013.
- 12) The Company is not a Nidhi Company.
- 13) In our opinion and according to the explanation given to us all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details of related party transactions have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause 3 (xiv) of the Order is not applicable to the Company.
- 15) In our opinion and according to the information and explanation given to us, the company has not generally entered into any non-cash transactions with its directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order is not applicable to the Company.
- 16) In our opinion and according to the information and explanation provided to us Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order is not applicable to the Company.

**For R.C. BAHETI & CO.**  
Chartered Accountants

Firm's registration No: 403034C


  
**RanjanBaheti**  
PARTNER



Membership No: 400993

Place: Bhopal  
Date: 29/06/2021  
UDIN: 21400993AAAADV3550





**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

**“Annexure B” to the Independent Auditor’s Report of even date on the Financial Statements of 3B BlackBio Biotech India Limited**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of 3B BlackBio Biotech India Limited (“the Company”) as of March 31, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the Guidance note) issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors’ Responsibility**


Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.







**R. C. BAHETI & CO.**  
**Chartered Accountants**  
**HEAD OFFICE**

24, Zone - II, M. P. Nagar, Near Som Distilleries  
Bhopal - 462011  
Ph. 0755 - 2557761, 4908690 MOB. 09826282060  
Email - [rameshchandrabaheti@yahoo.com](mailto:rameshchandrabaheti@yahoo.com)  
[ranjanbaheti@gmail.com](mailto:ranjanbaheti@gmail.com)

**Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


**Opinion**

In our opinion and best of the information and according to the explanations given to us the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

**For R.C. BAHETI & CO.**

Chartered Accountants

Firm's registration No: 403034C

  
**Ranjan Baheti**  
PARTNER



Membership No: 400993

Place: Bhopal

Date: 29/06/2021

UDIN: 21400993AAAADV3550





**M/S 3 B BLACKBIO BIOTECH INDIA LIMITED**  
**BALANCE SHEET AS AT 31st MARCH 2021**

Particulars	Note No.	As at 31-Mar-21	As at 31-Mar-20
<b>ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
Property , Plant , Equipments	2	3,02,35,759.19	1,77,76,058.21
Intangible Assets	3		12,58,010.50
Financial Assets			
(a) Investments	4	58,81,37,576.99	1,20,00,000.00
(b) Other Financial Assets	5	10,91,37,816.81	
Other Non Current Assets	6	2,02,235.00	
<b>Total Non Current Assets</b>		<b>72,77,13,387.99</b>	<b>3,10,34,068.71</b>
<b>CURRENT ASSETS</b>			
Inventories	7	2,16,92,375.94	85,41,665.00
Financial Assets			
(a) Trade Receivables	8	21,64,88,443.39	5,77,69,627.31
(b) Cash and Cash Equivalents	9	54,81,855.06	7,40,71,222.89
(c) Other Bank Balances	10	32,82,25,878.36	1,23,91,868.84
(d) Loans	11	9,82,764.00	6,29,055.00
Other Current Assets	12	39,12,49,031.49	1,81,97,860.77
<b>Total Current Assets</b>		<b>96,41,20,348.24</b>	<b>17,16,01,299.81</b>
<b>TOTAL ASSETS</b>		<b>169,18,33,736.23</b>	<b>20,26,35,368.52</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity Share Capital	13	1,02,75,000.00	1,02,75,000.00
Other Equity	14	128,19,45,355.86	16,04,36,960.69
<b>Total Equity</b>		<b>129,22,20,355.86</b>	<b>17,07,11,960.69</b>
<b>NON CURRENT LIABILITIES</b>			
Deffered Tax Liability	15	61,82,306.91	30,54,538.36
Other Non Current Liability	16	2,93,148.52	1,965.00
<b>Total Non Current Liabilities</b>		<b>64,75,455.43</b>	<b>30,56,503.36</b>
<b>CURRENT LIABILITIES</b>			
Financial Liabilities			
(a) Trade Payables	17	94,69,155.94	37,76,965.66
(b) Other Financial Liabilities	18	6,23,500.00	3,33,500.00
Provisions	19	38,30,45,269.00	2,47,56,438.81
<b>Total Current Liabilities</b>		<b>39,31,37,924.94</b>	<b>2,88,66,904.47</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>169,18,33,736.23</b>	<b>20,26,35,368.52</b>

Notes 1- 26 form integral part of financial statements  
for and on behalf of Board.

In terms of our report of even date.  
For R.C. Baheti & Co.  
Chartered Accountants  
Firm Registration No. 403034C

Ranjan Baheti  
Partner  
M.N. 400993  
Place:- Bhopal  
Dated :- 23/06/2021  
UDIN: 21400993AAAADV3550



Managing Director

Director





Sl. No.	Name of the Candidate	Roll No.	Grade	Remarks
1	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
2	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
3	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
4	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
5	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
6	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
7	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
8	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
9	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
10	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
11	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
12	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
13	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
14	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
15	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
16	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
17	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
18	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
19	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]
20	[Faint Name]	[Faint Roll No.]	[Faint Grade]	[Faint Remarks]

[Handwritten signature]

[Handwritten signature]



[Handwritten signature and text]

M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

STATEMENT OF PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2021

Particulars	Note No.	For the year ended March 31, 2021	For the year ended March 31, 2020
<b>INCOME</b>			
Revenue from Operations	20	214,21,35,163.82	15,36,28,728.21
Other Income	21	2,84,25,935.23	41,51,915.50
<b>TOTAL INCOME (I)</b>		<b>217,05,61,099.05</b>	<b>15,77,80,643.71</b>
<b>EXPENSES</b>			
Cost of raw material and components consumed	22	41,66,94,278.68	3,07,15,276.31
Purchase of Stock in Trade		31,38,526.00	
Change in Inventory of Finished Goods	23	14,70,614.00	4,56,703.62
Employee benefits expenses	24	3,03,40,757.69	1,32,56,174.76
Other expenses	25	21,52,45,307.04	1,58,15,803.48
Depreciation and amortization expenses	26	41,53,158.08	32,09,480.96
<b>TOTAL EXPENSE (II)</b>		<b>67,10,42,641.49</b>	<b>6,34,53,439.13</b>
<b>Profit Before exceptional items and Tax (I-II)</b>		<b>149,95,18,457.56</b>	<b>9,43,27,204.58</b>
Add: Exceptional Item (gain on sale of fixed assets)			50,000.00
<b>Profit Before tax</b>		<b>149,95,18,457.56</b>	<b>9,43,77,204.58</b>
Tax Expenses			
Current tax		37,42,06,392.00	2,35,65,820.16
Deferred tax		31,27,768.55	4,60,770.45
Previous Year Income Tax		6,75,901.84	5,38,432.71
<b>PROFIT FOR THE YEAR</b>		<b>112,15,08,395.17</b>	<b>7,07,33,722.16</b>
<b>Other Comprehensive Income/Loss</b>			
<b>(i) Items that will not be reclassified to profit and loss:</b>			
Equity instruments at fair value through other comprehensive income		1,04,913.63	(1,04,913.63)
<b>(ii) Income tax (expense)/credit relating to items that will not be reclassified to profit or loss</b>			
<b>Total Comprehensive Income</b>		<b>1,04,913.63</b>	<b>(1,04,913.63)</b>
<b>Total comprehensive income/(loss) for the year</b>		<b>112,16,13,308.80</b>	<b>7,06,28,808.53</b>
EPS		1,091.59	68.74

Notes 1- 26 form integral part of financial statements  
for and on behalf of Board.

In terms of our report of even date.

For R.C. Baheti & Co.  
Chartered Accountants  
Firm Registration No. 403034C

  
Ranjan Baheti  
Partner  
M.N. 400993  
Place:- Bhopal  
Dated :- 29/06/2021  
UDIN: 21400993AAAADV3550



  
Managing Director

  
Director



[Redacted header information]

[Redacted header information]

1	...	...
2	...	...
3	...	...
4	...	...
5	...	...
6	...	...
7	...	...
8	...	...
9	...	...
10	...	...

...	...
...	...
...	...
...	...
...	...
...	...
...	...
...	...
...	...
...	...

...	...
...	...
...	...

[Faint, mostly illegible text in the right column, possibly containing a list of items or a report summary.]

*[Handwritten signatures and notes in the bottom left quadrant.]*



*[Handwritten signature and additional notes in the bottom right quadrant.]*

**M/S 3 B BLACK BIO BIOTECH INDIA LIMITED**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2021**

PARTICULARS	2021	2020
<b>I. Cash Flow From Operating Activities</b>		
Net Profit/(Loss) as per Statement of Profit & Loss	-1,12,15,08,395.17	7,07,33,722.16
Add:- Provision for Taxation	37,80,10,062.39	2,36,43,482.42
<b>Net Profit before Working Capital Changes</b>	<b>1,49,95,18,457.56</b>	<b>9,43,77,204.58</b>
Add:- Depreciation and Amortization	41,53,158.08	32,09,480.96
Less:- Gain on sale of Fixed Assets	-	(50,000.00)
Interest Earned	(2,71,25,751.46)	(36,90,429.25)
Gain on investments carried at fair value through profit and loss	(10,50,894.28)	-
	<b>1,47,54,94,969.90</b>	<b>9,38,46,256.29</b>
<b>Changes In Working Capital</b>		
Less :- Increase in Inventories	1,31,50,710.94	1,63,547.00
Less:- Increase in Trade Receivables	15,87,18,816.08	1,40,76,988.68
Less:- Increase in Other Current assets	93,83,347.75	13,59,526.37
Less:- Increase in Other Non-Current assets	2,02,235.00	-
Add:- Increase in Trade Payables	56,92,190.28	14,68,694.73
Add:- Increase in Provision	76,48,258.35	6,32,328.58
Add:- Increase in Other Non-Current Liability	2,91,183.52	-
Add:- Increase in Other Current Liability	2,90,000.00	-
<b>Net Profit /(Loss) after Working Capital Adjustment</b>	<b>1,30,79,61,492.28</b>	<b>3,03,47,217.55</b>
Less:- Income Tax Paid	(37,99,36,954.97)	(62,69,132.00)
Previous Year Income Tax Paid	(79,72,590.00)	(48,93,060.00)
<b>Net Cash Flow from Operating Activities</b>	<b>92,00,51,947.31</b>	<b>5,91,85,025.55</b>
<b>II. Cash Flow From Investing Activities</b>		
Loans & Deposits repaid during the year	(3,53,709.00)	4,88,700.00
Fixed Assets Purchased	(1,65,04,848.56)	(50,82,199.03)
Fixed Assets Sold	11,50,000.00	9,00,000.00
Interest Received	2,49,98,517.46	36,90,429.25
Mutual Funds/Bonds Purchased	(61,44,49,062.71)	-
Bonds Sold/Matured	4,14,89,614.00	-
Bank balances not considered as Cash & cash Equivalents	(42,49,71,826.33)	(40,48,368.84)
<b>Net Cash Flow From Investing Activities</b>	<b>(98,86,41,315.14)</b>	<b>(40,51,438.62)</b>
<b>III. Cash Flow From Financing Activities</b>		
Interim Dividend ( Gross Dividend) 2019-20	-	(1,23,87,058.00)
Dividend ( Gross Dividend) 2018-19	-	(41,60,665.00)
Proceed From Issue of Equity Shares+	-	2,87,50,000.00
<b>Net Cash Flow From Financing Activities</b>	<b>-</b>	<b>1,22,02,277.00</b>
<b>Net Increase in Cash &amp; Cash Equivalents</b>	<b>(6,85,89,367.83)</b>	<b>6,73,35,863.93</b>
<b>Cash &amp; Cash Equivalents at beginning of the year</b>	<b>7,40,71,222.89</b>	<b>67,35,358.96</b>
<b>Cash &amp; Cash Equivalents at end of the year</b>	<b>54,81,855.06</b>	<b>7,40,71,222.89</b>

Cash Flow Statement has been prepared under the indirect method as set out in Ind AS-7

In terms of our report attached.  
 For R.C.Baheti & Co.  
 Chartered Accountants  
 Reg No. -403034C

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Managing Director

Director

*Ranjan Baheti*  
 CA. Ranjan Baheti  
 Partner  
 M.No. 400993



Place: Bhopal  
 Dated: 23/06/2021  
 UDIN: 21400993AAAADV3550

Left column of text, possibly a list or index, containing several lines of illegible characters.

Second column of text, continuing the list or index from the first column.

Third column of text, containing further entries or details.

Right column of text, containing several lines of illegible characters.

Second right column of text, continuing the text from the first right column.

Third right column of text, containing further text.

Fourth right column of text, containing further text.

Handwritten signatures or initials in the lower middle section of the page.



Handwritten text and possibly a signature in the bottom right corner.

Statement of Changes in Equity

For The Year Ended 31st March 2021

A) Equity Share Capital

Particulars	Amount (Rs.)
Balance at 01 April, 2020	1,02,75,000.00
<b>Balance at 31st March, 2021</b>	<b>1,02,75,000.00</b>

B) Other Equity

Particulars	Securities Premium	Retained Earnings	Other Equity	
			Money Received Against Share Warrants	Equity instruments through OCI
Balance as on 01st April 2020	3,60,00,000.00	12,43,32,047.06	0.00	1,04,913.63
Add:				
Profit for the Year		112,15,08,395.17		
<b>Total Comprehensive income/(loss) for the year</b>	<b>3,60,00,000.00</b>	<b>124,58,40,442.23</b>	<b>0.00</b>	<b>1,04,913.63</b>
Issue of Equity shares through conversion of preferential share warrants				
Equity instruments at fair value through other comprehensive income		1,04,913.63		(1,04,913.63)
Dividend including Dividend Distribution Tax				
<b>Balance as on 31st March 2021</b>	<b>3,60,00,000.00</b>	<b>124,59,45,355.86</b>		







## M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

### 2. PROPERTY, PLANT & EQUIPMENT

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Property, Plant & Equipments	3,02,35,759.19	1,77,76,058.21
<b>Total(Rs.)</b>	<b>3,02,35,759.19</b>	<b>1,77,76,058.21</b>

### 3. INTANGIBLE ASSETS

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Intangible Assets	-	12,58,010.50
<b>Total(Rs.)</b>	<b>-</b>	<b>12,58,010.50</b>

### 4. NON CURRENT INVESTMENTS

PARTICULARS	As at 31.03.2021	As at 31.03.2020
-------------	------------------	------------------

#### Non-current investments

##### Bonds - At Cost

8.5% Bank Of Baroda Perpetual Fund(Including Accrued Interest)	5,18,66,000.62	-
7.33% Tata Capital Housing Finance Ltd. (Bonds) (Including Accrued Interest)	2,06,01,913.00	-
	<b>7,24,67,913.62</b>	<b>-</b>

##### Mutual Funds - At Fair Value

SBI Arbitrage Mutual Fund	45,49,489.04	40,00,000.00
SBI Equity Fund	99,08,613.21	80,00,000.00
Aditya Birla Sun Life Mutual Fund	5,03,35,770.02	-
Aditya Birla Sun Life Income Fund	5,03,87,220.57	-
IDFC Banking PSU Debt Mutual Fund	5,04,76,680.49	-
IDFC Bond Fund- Short term plan	5,04,36,186.08	-
Kotak Dynamic Bond fund	2,51,47,888.59	-
Kotak Medium Term Fund	2,51,77,747.83	-
Kotak - Savings Fund Growth (Reg) Plan	1,00,638.55	-
SBI Dynamic Bond Fund	5,02,30,379.20	-
SBI Magnum Medium Duration Fund- Growth	5,00,76,767.02	-
SBI Short Term Debt Fund - Reg. Growth	5,00,26,113.75	-
	<b>41,68,53,494.35</b>	<b>1,20,00,000.00</b>

##### Government Bonds - At Cost

8.3% National Highway Authority of India Bonds(Including Accrued Interest)	1,74,79,297.79	-
6.95% Power Finance Corporation Non-Convertible Debentures (Including Accrued Interest)	5,06,56,917.00	-
7.97% REC Perpetual Bonds(Including Accrued Interest)	3,06,79,954.23	-
	<b>9,88,16,169.02</b>	<b>-</b>

Total	<b>58,81,37,576.99</b>	<b>1,20,00,000.00</b>
-------	------------------------	-----------------------

### 5. Other Financial Assets

PARTICULARS	As at 31.03.2021	As at 31.03.2020
HDFC STDR A/c *	10,91,37,816.81	-
	<b>10,91,37,816.81</b>	<b>-</b>

\*Bank Term deposit with maturity more than 12 months from balance sheet date





## M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

### i. Other Non Current Assets

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Wellkang Limited U.K.(Prepaid Expenses) (Biennial Fee)	2,02,235.00	
	<u>2,02,235.00</u>	

### 7. INVENTORIES

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Inventories of Raw Material,Packing Material and finished goods	2,16,92,375.94	85,41,665.00
<b>Total(Rs.)</b>	<u>2,16,92,375.94</u>	<u>85,41,665.00</u>

### 8. TRADE RECEIVABLES

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Outstanding for a period exceeding six months (Unsecured but Considered good )	16,14,469.25	3,94,562.70
Others	21,48,73,974.14	5,73,75,064.61
<b>Total(Rs.)</b>	<u>21,64,88,443.39</u>	<u>5,77,69,627.31</u>

### 9. CASH AND CASH EQUIVALENTS

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Cash in hand	6,04,129.38	5,38,688.75
Indus Ind Bank	15,380.34	11,626.91
SBI Current A/c(Including Auto Swipe FDS)	30,07,769.01	7,33,67,373.96
SBI Preferential Warrant A/c		15,000.00
State Bank of India (T.T. Nagar ) OD A/c	1,93,780.79	1,38,533.27
HDFC Bank CD A/c	16,60,795.54	
<b>Total(Rs.)</b>	<u>54,81,855.06</u>	<u>7,40,71,222.89</u>

### 10. Other Bank Balances

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Indus Ind STDR A/c*	53,25,184.30	93,27,184.30
Accrued Interest- Indusind Bank*	3,78,947.06	3,22,118.54
SBI STDR A/c*	31,20,00,000.00	
Accrued Interest- SBI	96,43,747.00	23,89,066.00
SBI Interim Dividend A/c (2019-20)	3,00,000.00	10,000.00
SBI Interim Dividend A/c (2018-19)	1,40,500.00	1,40,500.00
SBI Interim Dividend A/c (2017-18)	2,03,000.00	2,03,000.00
SBI BG A/c	1,84,500.00	
SBI Forward Contt. Margin STDR	50,000.00	
	<u>32,82,25,878.36</u>	<u>1,23,91,868.84</u>

\*Bank Term deposit with maturity more than 3 months



Sl. No.	Name of the Candidate	Grade	Percentage
1	...	...	...
2	...	...	...
3	...	...	...
4	...	...	...
5	...	...	...
6	...	...	...
7	...	...	...
8	...	...	...
9	...	...	...
10	...	...	...
11	...	...	...
12	...	...	...
13	...	...	...
14	...	...	...
15	...	...	...
16	...	...	...
17	...	...	...
18	...	...	...
19	...	...	...
20	...	...	...
21	...	...	...
22	...	...	...
23	...	...	...
24	...	...	...
25	...	...	...
26	...	...	...
27	...	...	...
28	...	...	...
29	...	...	...
30	...	...	...
31	...	...	...
32	...	...	...
33	...	...	...
34	...	...	...
35	...	...	...
36	...	...	...
37	...	...	...
38	...	...	...
39	...	...	...
40	...	...	...
41	...	...	...
42	...	...	...
43	...	...	...
44	...	...	...
45	...	...	...
46	...	...	...
47	...	...	...
48	...	...	...
49	...	...	...
50	...	...	...



# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## 11. DEPOSITS AND ADVANCES

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Deposits others (incl. security deposit with various govt. dept)	6,04,055.00	5,79,055.00
Advances to Staff	3,78,709.00	50,000.00
<b>Total(Rs.)</b>	<b>9,82,764.00</b>	<b>6,29,055.00</b>

## 12. OTHER CURRENT ASSETS

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Other Duties & Taxes	43,251.40	43,251.40
Advance tax and TDS	37,98,41,015.86	1,62,69,132.00
TCS (Input Credit)	95,939.11	
GST Recievable	5,03,709.48	6,86,805.37
Cenvat (Excise)	12,391.00	12,391.00
Balance in PLA Account	56,629.00	56,629.00
Income Tax Deposit(2010-11)	6,180.00	6,180.00
Expenses on Merger(under progress)	3,23,000.00	3,23,000.00
Prepaid Salary		3,15,000.00
Advance To Supplier	1,01,00,685.24	
MEIS License	2,66,230.40	4,85,472.00
<b>Total(Rs.)</b>	<b>39,12,49,031.49</b>	<b>1,81,97,860.77</b>





# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## 13. EQUITY SHARE CAPITAL

PARTICULARS	As at 31.03.2021		As at 31.03.2020	
<u>Authorised Share Capital</u>	<u>No. of Share</u>		<u>No. of Share</u>	
Equity Share of Rs.10/- each	1200000	1,20,00,000.00	1200000	1,20,00,000.00
<u>Issued Subscribed and Paid up</u>				
Equity Share of Rs.10/- each fully paid up (Previous year Rs.10/- each)	1027500	1,02,75,000.00	1027500	1,02,75,000.00
<b>Total(Rs.)</b>		<b>1,02,75,000.00</b>		<b>1,02,75,000.00</b>

### Note:- 13.1

The reconciliation of the number of shares outstanding is set out below:

PARTICULARS	As at 31.03.2021	As at 31.03.2020
Balance at the commencement of the year	10,27,500.00	6,27,500.00
Add: Shares issued on conversion of Warrants		4,00,000.00
Balance at the end of the year	<b>10,27,500.00</b>	<b>10,27,500.00</b>

### Note:- 13.2

The holders of the equity share are entitled to receive dividends as declared from time to time and are entitled to one vote per share at the meeting of the company .

### Note :-13.3

Details of shareholding more than 5% of the shares

Particulars	As at 31.03.2021		As at 31.03.2020	
	No. of Share	% of Share holding	No. of Share	% of Share holding
M/s Kilpest India Limited , Bhopal	898500	87.45	898500	87.45
M/s 2B Blackbio ,S.L. Spain	29000	2.82	29000	2.82
Shri Nikhil Kuber Dubey	10000	0.97	10000	0.97
Shri Dharendra Dubey	40000	3.89	40000	3.89
Shri Prateek Goel	50000	4.87	50000	4.87
	<b>1027500</b>	<b>100.00</b>	<b>1027500</b>	<b>100.00</b>

## 14. OTHER EQUITY

PARTICULARS	As at 31.03.2021		As at 31.03.2020	
Surplus :-				
Opening balance	12,43,32,047.06		6,60,90,296.53	
Add:-Profit after tax for the year	112,16,13,308.80		7,06,28,808.53	
Less: Interim Dividend			(1,02,75,000.00)	
Less: Dividend Distribution Tax	-	1,24,59,45,355.86	(21,12,058.00)	12,43,32,047.06
Equity instruments through OCI				1,04,913.63
Securities Premium Account		3,60,00,000.00		3,60,00,000.00
<b>Total (A)</b>		<b>1,28,19,45,355.86</b>		<b>16,04,36,960.69</b>

### Security premium

The amount received in excess of face value of the equity shares, in relation to issuance of equity, is recognised in Securities Premium Reserve.



Section header or title at the top of the main content area.

Item 1	Category 1	Value 1	Category 2	Value 2
Item 2	Category 1	Value 1	Category 2	Value 2
Item 3	Category 1	Value 1	Category 2	Value 2

Section header or title for the second table.

Item 4	Category 1	Value 1	Category 2	Value 2
Item 5	Category 1	Value 1	Category 2	Value 2
Item 6	Category 1	Value 1	Category 2	Value 2

Section header or title for the third table.

Item 7	Category 1	Value 1	Category 2	Value 2
Item 8	Category 1	Value 1	Category 2	Value 2
Item 9	Category 1	Value 1	Category 2	Value 2

Section header or title for the fourth table.

Item 10	Category 1	Value 1	Category 2	Value 2
Item 11	Category 1	Value 1	Category 2	Value 2
Item 12	Category 1	Value 1	Category 2	Value 2

Section header or title for the fifth table.

Item 13	Category 1	Value 1	Category 2	Value 2
Item 14	Category 1	Value 1	Category 2	Value 2
Item 15	Category 1	Value 1	Category 2	Value 2





## M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

15. DEFERRED TAX LIABILITY	As at 31.03.2021	As at 31.03.2020
PARTICULARS		
Opening	30,54,538.36	35,15,308.81
Add : Current year's	31,27,768.55	(4,60,770.45)
<b>Total(Rs.)</b>	<b>61,82,306.91</b>	<b>30,54,538.36</b>

16. OTHER NON CURRENT LIABILITY	As at 31.03.2021	As at 31.03.2020
PARTICULARS		
Security Deposit	1,965.00	1,965.00
Nirman Share Brokers Pvt. Ltd.	(12,597.06)	
Advance From Customers	3,03,780.58	
<b>Total(Rs.)</b>	<b>2,93,148.52</b>	<b>1,965.00</b>

17. TRADE PAYABLE	As at 31.03.2021	As at 31.03.2020
PARTICULARS		
Trade Payable	28,19,526.07	21,99,338.49
Other Payables	66,49,629.87	15,77,627.17
<b>Total(Rs.)</b>	<b>94,69,155.94</b>	<b>37,76,965.66</b>

18. OTHER FINANCIAL LIABILITIES	As at 31.03.2021	As at 31.03.2020
PARTICULARS		
Unclaimed Dividend (18-19 )	1,30,500.00	1,30,500.00
Unclaimed Dividend.(17-18 )	2,03,000.00	2,03,000.00
Unclaimed Dividend (19-20 )	2,90,000.00	
<b>Total (Rs.)</b>	<b>6,23,500.00</b>	<b>3,33,500.00</b>

19. PROVISIONS	As at 31.03.2021	As at 31.03.2020
PARTICULARS		
TDS Payable	8,98,110.00	3,39,387.00
TCS Payable	47,943.00	
Professional Tax	27,824.00	56,639.00
Audit fees	1,00,000.00	54,000.00
Provision for Income Tax	37,42,06,392.00	2,35,65,820.16
GST Payable		7,40,592.65
Performance Bonus (Covid 19) Payable	77,65,000.00	
<b>Total (Rs.)</b>	<b>38,30,45,269.00</b>	<b>2,47,56,438.81</b>





**M/S 3 B BLACKBIO BIOTECH INDIA LIMITED**

**20. REVENUE FROM OPERATIONS**

PARTICULARS	For the year ended:31.03.2021	For the year ended:31.03.2020
Sales of products		
Diagnostics Kits & Life Sciences	2,14,06,51,782.38	14,70,52,093.46
Export Sale	14,83,381.44	65,76,634.75
<b>Total(Rs.)</b>	<b>2,14,21,35,163.82</b>	<b>15,36,28,728.21</b>

**21. OTHER INCOME**

PARTICULARS	For the year ended:31.03.2021	For the year ended:31.03.2020
Interest on Fixed Deposit	2,15,68,779.46	36,90,429.25
Interest income on Bonds	55,56,972.00	-
Custom Duty Drawback	42,885.00	69,631.00
Freight Charges Export	1,26,166.60	3,91,855.25
Freight Charges Collected	18,400.00	-
Gain on investments carried at fair value through profit and loss* (Net of loss on sale of Investment)	10,50,894.28	-
Exchange gain (Net)**	61,837.89	-
<b>Total(Rs.)</b>	<b>2,84,25,935.23</b>	<b>41,51,915.50</b>

\*Gain on investments carried at fair value through profit and loss      47,53,494.35  
 Less: Loss on sale of current investment      (37,02,600.07)  
10,50,894.28

Exchange gain (Net)\*\*

Exchange gain      80,918.21  
 Less: Exchange Loss      (19,080.32)  
61,837.89

**22. RAW MATERIAL CONSUMED**

PARTICULARS	For the year ended:31.03.2021	For the year ended:31.03.2020
Opening Stock of Raw Material	51,31,736.00	47,45,099.00
Add:- Purchased during the year	43,13,15,603.62	3,11,01,913.31
Less:- Closing Stock of Raw Material	1,97,53,060.94	51,31,736.00
<b>Total(Rs.)</b>	<b>41,66,94,278.68</b>	<b>3,07,15,276.31</b>

**23. CHANGE IN INVENTORY OF FINISHED GOODS**

PARTICULARS	For the year ended:31.03.2021	For the year ended:31.03.2020
Opening stock of finished goods	34,09,929.00	36,33,019.00
Add: Purchase of Finished Goods	-	2,33,613.62
Less : Closing stock of finished goods	19,39,315.00	34,09,929.00
<b>Total(Rs.)</b>	<b>14,70,614.00</b>	<b>4,56,703.62</b>

**24. EMPLOYEE BENEFIT EXPENSE**

PARTICULARS	For the year ended:31.03.2021	For the year ended:31.03.2020
Salary and other emoulements	1,55,80,733.00	1,30,31,597.00
Staff and labour welfare	4,52,524.69	2,24,577.76
Performance Bonus	1,43,07,500.00	-
<b>Total(Rs.)</b>	<b>3,03,40,757.69</b>	<b>1,32,56,174.76</b>





**M/S 3 B BLACKBIO BIOTECH INDIA LIMITED**

**25. OTHER EXPENSE**

PARTICULARS	For the year ended 31.03.2021	For the year ended 31.03.2020
Advertisement & Publicity	10,42,985.52	6,85,263.50
Audit Fees	1,00,000.00	35,000.00
Bank Commission & Charges	14,47,080.46	4,65,951.04
Carrige Outward Expenses	67,70,511.86	9,02,857.36
Commission On Sales	11,13,96,457.00	7,37,768.00
Commission to Director	3,48,00,000.00	13,37,980.00
Computer Maintenance	43,767.07	20,143.22
Conveyance	10,49,001.00	5,65,193.00
Conference Expense	6,97,220.00	11,97,567.00
CSR	8,96,715.00	1,98,081.25
Garden Maintainence	1,23,890.00	72,000.00
General Maintainence	3,94,973.23	1,00,754.48
Discount Allowed	9,96,952.00	1,09,728.00
Electricity Exp	1,35,223.00	5,40,000.00
Fuel & Power	5,84,713.44	47,909.00
Festival Expenses	5,74,196.00	19,361.00
Insurance Expenses	-	8,326.00
Interest on GST	1,27,749.00	-
Lab Expenses	21,48,046.00	-
LD Deducted By Hites	8,68,720.00	2,04,400.00
Legal & Professional Fees	-	1,03,085.30
Loss on foreign currency transaction	2,87,090.14	19,091.00
Machinery Maintenance	80,286.11	3,128.80
Medical Expenses	3,98,269.26	-
Miscellaneous Expenses	11,66,280.63	3,83,008.95
Office & General Expenses	42,13,218.10	10,78,137.26
Packing & Forwarding	36,294.74	32,711.44
Postage	2,68,749.17	-
Packing Material (Freight)	5,89,548.00	2,23,860.00
Printing/Stationery/Photocopy Expenses	13,43,580.94	2,66,853.04
Packing Material(Ice and Other)	3,74,46,686.22	22,02,569.13
Rates taxes and fees	8,60,256.00	4,65,192.00
Rent Expenses	21,23,715.00	20,49,390.00
Research and Development Expenses	-	600.00
Staff Skill Development	6,59,428.58	91,253.00
Selling, Distribution & Sales Promotion Expenses	-	67,712.00
Software Development	22,758.83	10,329.00
Stores & Spare Parts Consumed	1,39,361.63	1,80,720.71
Subscription & Online advertisement	38,329.29	40,528.76
Telephone Expenses	13,73,211.30	13,42,203.31
Travelling & Conveyance Expenses	-	7,096.88
Vehicle Maintainence	42.52	50.05
Round Off	-	-
Total (Rs.)	<u>21,52,45,307.04</u>	<u>1,58,15,803.48</u>

**26. DEPRICIATION & AIMMORTISATION EXPENSE**

PARTICULARS	For the year ended 31.03.2021	For the year ended 31.03.2020
Depreciation on tangible assets	41,53,158.08	32,09,480.96
Total(Rs.)	<u>41,53,158.08</u>	<u>32,09,480.96</u>





# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## Trade Payables

Particulars	Amount As at 31.03.2021
Advanced Microdevices Pvt.Ltd.	198,028.00
Amplicon Biotech	244,800.00
A'Niche Infotech Solutions Pvt.Ltd,Mumbai	307,419.00
Bhargava Traders	323,545.00
Bioaid Lab Solutions	25,336.00
Dhl Express Ltd.	65,879.84
Eurofins Genomics India Pvt.Ltd,Bangalore	3,984.00
Genaxy Scientific P Ltd, Solan.	134,992.00
I.R. System	114,216.00
Jain Marketing	12,160.00
Peekay Scientific Glasswares	602.00
Perfect Marketing	24,215.00
Qiagen India Pvt Ltd,New Delhi.	69,451.40
R.N. Traders	478,001.00
Rashmi Enterprises	421,326.00
Sahagene Hyderabad	2,637.60
S.K.Traders	328,161.23
Sigma Aldrich Chemicals Pvt.Ltd.,Bangalore	64,656.00
Symbiosis spz.o.o	116.00
<b>Total</b>	<b>2,819,526.07</b>

## Sundry Creditors for Expenses

Particulars	Amount As at 31.03.2021
Apex Express Cargo Solutions	1,324,838.00
Blue Dart Express Ltd.	163.00
Ca Rahul Jain.	18,500.00
Gift & Gifts	137,500.00
International Certification Services P. Ltd.	2,950.00
Krishna & Saurastri	7,174.00
Omkar Clearing	16,019.00
Ravi Kumar	190,000.00
Shree Satyam	16,770.00
Shree Maruti Courier Service Pvt. Ltd.	4,792.00
Dhirendra Dubey	2,310,000.50
N K Dubey	1,860,000.50
Staff & Directors	7,60,922.87
<b>Total</b>	<b>66,49,629.87</b>

Total

9,469,155.94







# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

Other Payables

Advance from Customers

Particulars	Amount As at 31.03.2021
Sanbiomed	63,130.00
Pristine Bio Chemicals, Bhubaneshwar	16,636.62
Deep Enterprises	11.20
Shayadri speciality labs	2.76
Scientific traders	224,000.00
<b>Total</b>	<b>303,780.58</b>





# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## Trade Receivables

Particulars	Amount	
	As at 31.03.2021 Less than 6 months	As at 31.03.2021 More than 5 months
Abhilash Tiwari	1,757.00	
Cancer Institute	-	7,376.00
Chemi-Health Diagnostics	-	774.20
Chirayu Medical College & Hospital Bhopal	1,24,964.00	-
Dev Enterprises	47,880.00	-
Director, Aiims-Bhopal	49,796.00	-
Dr Anita Tilwari	-	10.00
G.C.Lifesciences	34,03,108.00	-
Hiya Scientific Solutions	8,080.00	-
Malabar Cancer Centre	12,50,956.00	-
Modern X-Ray Pathology	94,096.00	-
New India Traders	-	49.00
Premas Biotech Pvt. Ltd.	-	7,127.20
Sri Sathya Sai Sanjeevani International	11,800.00	-
Vivid Global Technologies	17,79,34,805.35	-
Meenakshi Labs	-	0.80
Regene Biologics	2,89,348.27	-
KR Instruments & chemicals	-	23,912.00
Arts & science college, pullgaon	-	2,266.55
Central India Institute Of Medical sciences	25,550.00	-
LMMFs- Deenanath Mangeskar Hospital & Res. Centre	1,36,157.00	-
BIOMART, Delhi	-	68,500.00
Scientific Research & Instrument	-	3,859.50
SNM Hospital, Leh	1,39,01,305.00	-
CSIR - National Chemical Laboratory (NCL)	2,79,300.00	-
Directorate Of Disaster Management , Port Blair	78,49,188.00	-
Kilpest India Ltd. - Export	94,65,767.52	-
Miscellaneous Debtors	-	39,196.00
Swami Ramanand Teerth Rural Govt. Medical College	-	11,63,478.00
Techtron, Kuwait	116.00	-
Vilasrao Deshmukh Govt. Institute of Medical Sciences	-	2,97,920.00
<b>Total(B)</b>	<b>21,48,73,974.14</b>	<b>16,14,469.25</b>
<b>Total Trade Receivables(A+B)</b>		<b>21,64,88,443.39</b>
Trade receivables more than six months		16,14,469.25
Others		21,48,73,974.14





# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## Advance to Supplier

Particulars	Amount As at 31.03.2021
Biolegio B.V.Netherlands.	19,64,693.32
Biosearch Technologies, Usa	1,40,500.04
D.S.Enterprises	66,080.00
Dss Takara Bio India Pvt.Ltd	39,28,330.00
Fapon International Ltd.	0.16
Gene Direx Inc. Taiwan	4,55,645.44
Genetix Biotech Asia Pvt. Ltd.	5,504.00
Hathor Corporate Advisors Llp	2,00,000.00
Invitrogen Bioservices India P Ltd	29.97
LGC Biosearch Technologies,Denmark.	2,03,294.00
New India Assurance Co. Ltd.	4,073.00
Sangon Biotech ( Shanghai ) Co.:Ltd	28,21,158.31
Umbrella Lifescience	3,11,377.00
	<u>1,01,00,685.24</u>



1948

1. 1948  
2. 1948  
3. 1948  
4. 1948  
5. 1948  
6. 1948  
7. 1948  
8. 1948  
9. 1948  
10. 1948

1. 1948  
2. 1948  
3. 1948  
4. 1948  
5. 1948  
6. 1948  
7. 1948  
8. 1948  
9. 1948  
10. 1948

1949



**3 B BLACKBIO BIOTECH INDIA LIMITED**  
**PROPERTY, PLANT & EQUIPMENT AND DEPRECIATION AS ON 31.03.2021**

S.No	Particular	Gross Block			Depreciation			Net Block			
		Balance as on 01.04.2020	Addition during the year	Deductions/Adjustment	Balance as on 31.03.2021	As on 01.04.2020	For the Year	Deductions/Adjustment	Total	As on 31.03.2021	As on 31.03.2020
1	Electrical Equipments	151,000.00	442,138.45	-	593,138.45	45,464.95	39,227.01	-	84,691.96	508,446.49	105,535.05
2	Equipments	522,048.09	13,600.00	-	535,648.09	445,189.54	18,277.55	-	463,467.09	72,181.00	76,858.55
3	Furniture	274,038.00	290,626.00	-	564,664.00	140,170.95	34,196.94	-	174,367.89	390,296.11	133,867.05
4	Computer	811,548.77	220,000.00	-	1,031,548.77	499,187.72	156,865.42	-	656,053.14	375,495.63	312,361.05
5	Computer(R&D)	286,577.13	-	-	286,577.13	68,975.23	90,749.42	-	159,724.65	126,852.48	217,601.90
6	Lab Equipments	1,816,495.50	62,227.12	-	1,878,722.62	660,001.66	187,684.60	-	847,686.26	1,031,036.36	1,156,493.84
7	R&D Equipments	18,297,138.36	14,475,869.31	1,150,000.00	31,623,007.67	2,523,797.59	2,333,468.18	-	4,857,265.77	26,765,741.90	15,773,340.77
8	Plant & Machinery	-	1,000,387.68	-	1,000,387.68	-	34,678.46	-	34,678.46	965,709.22	-
	<b>TOTAL</b>	<b>22,158,845.85</b>	<b>16,504,848.56</b>	<b>1,150,000.00</b>	<b>37,513,694.41</b>	<b>4,382,787.64</b>	<b>2,895,147.58</b>	<b>-</b>	<b>7,277,935.22</b>	<b>30,235,759.19</b>	<b>17,776,058.21</b>

Figures of Previous Years		17,926,646.82	5,082,199.03	850,000.00	22,158,845.85	2,431,317.18	1,951,470.46	-	4,382,787.64	17,776,058.21	15,495,329.64
---------------------------	--	---------------	--------------	------------	---------------	--------------	--------------	---	--------------	---------------	---------------

S.No	Particular	Gross Block			Depreciation			Net Block			
		Balance as on 01.04.2020	Addition during the year	Deductions/Adjustment	Balance as on 31.03.2021	As on 01.04.2020	For the Year	Total	As on 31.03.2021	As on 31.03.2020	
1	Technology Fees	7,548,063.00	-	-	7,548,063.00	6,290,052.50	1,258,010.50	7,548,063.00	-	1,258,010.50	-
	<b>TOTAL</b>	<b>7,548,063.00</b>	<b>-</b>	<b>-</b>	<b>7,548,063.00</b>	<b>6,290,052.50</b>	<b>1,258,010.50</b>	<b>7,548,063.00</b>	<b>-</b>	<b>1,258,010.50</b>	<b>-</b>

Figures of Previous Years		7,548,063.00	-	-	7,548,063.00	5,032,042.00	1,258,010.50	6,290,052.50	1,258,010.50	2,516,021.00
---------------------------	--	--------------	---	---	--------------	--------------	--------------	--------------	--------------	--------------







# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## Trade Payables

Particulars	Amount As at 31.03.2021
Advanced Microdevices Pvt.Ltd.	1,98,028.00
Amplicon Biotech	2,44,800.00
A'Niche Infotech Solutions Pvt.Ltd,Mumbai	3,07,419.00
Bhargava Traders	3,23,545.00
Bioaid Lab Solutions	25,336.00
Dhl Express Ltd..	65,879.84
Eurofins Genomics India Pvt.Ltd,Bangalore	3,984.00
Genaxy Scientific P Ltd, Solan.	1,34,992.00
I.R. System	1,14,216.00
Jain Marketing	12,160.00
Peekay Scientific Glasswares	602.00
Perfect Marketing	24,215.00
Qiagen India Pvt Ltd,New Delhi.	69,451.40
R.N. Traders	4,78,001.00
Rashmi Enterprises	4,21,326.00
Sahagene Hyderabad	2,637.60
S.K.Traders	3,28,161.23
Sigma Aldrich Chemicals Pvt.Ltd.,Bangalore	64,656.00
Symbiosis spz.o.o	116.00
<b>Total</b>	<b>28,19,526.07</b>

## Sundry Creditors for Expenses

Particulars	Amount As at 31.03.2021
Apex Express Cargo Solutions	13,24,838.00
Blue Dart Express Ltd.	163.00
Ca Rahul Jain.	18,500.00
Gift & Gifts	1,37,500.00
International Certification Services P. Ltd.	2,950.00
Krishna & Saurastri	7,174.00
Omkar Clearing	16,019.00
Ravi Kumar	1,90,000.00
Shree Satyam	16,770.00
Shree Maruti Courier Service Pvt. Ltd.	4,792.00
Dhirendra Dubey	23,10,000.50
N K Dubey	18,60,000.50
Staff & Directors	7,60,922.87
<b>Total</b>	<b>66,49,629.87</b>



Name

Roll No.

Date

Q.1. Define the following terms:  
 (a)  $\frac{1}{2}$  mole of  $H_2$   
 (b)  $10^{-2}$  mole of  $NaCl$   
 (c)  $10^{-3}$  mole of  $CaCl_2$   
 (d)  $10^{-4}$  mole of  $Na_2CO_3$   
 (e)  $10^{-5}$  mole of  $NaOH$   
 (f)  $10^{-6}$  mole of  $HCl$   
 (g)  $10^{-7}$  mole of  $H_2SO_4$   
 (h)  $10^{-8}$  mole of  $Na_2SO_4$   
 (i)  $10^{-9}$  mole of  $Na_2CO_3$   
 (j)  $10^{-10}$  mole of  $NaOH$

Q.2. Calculate the number of molecules in 100 g of  $H_2O$ .  
 Q.3. Calculate the number of molecules in 100 g of  $CO_2$ .  
 Q.4. Calculate the number of molecules in 100 g of  $SO_2$ .  
 Q.5. Calculate the number of molecules in 100 g of  $SO_3$ .  
 Q.6. Calculate the number of molecules in 100 g of  $NaCl$ .  
 Q.7. Calculate the number of molecules in 100 g of  $CaCl_2$ .  
 Q.8. Calculate the number of molecules in 100 g of  $Na_2CO_3$ .  
 Q.9. Calculate the number of molecules in 100 g of  $NaOH$ .  
 Q.10. Calculate the number of molecules in 100 g of  $HCl$ .  
 Q.11. Calculate the number of molecules in 100 g of  $H_2SO_4$ .  
 Q.12. Calculate the number of molecules in 100 g of  $Na_2SO_4$ .

Q.13. Define the following terms:

Name

Roll No.

Date

Q.1. Define the following terms:  
 (a)  $\frac{1}{2}$  mole of  $H_2$   
 (b)  $10^{-2}$  mole of  $NaCl$   
 (c)  $10^{-3}$  mole of  $CaCl_2$   
 (d)  $10^{-4}$  mole of  $Na_2CO_3$   
 (e)  $10^{-5}$  mole of  $NaOH$   
 (f)  $10^{-6}$  mole of  $HCl$   
 (g)  $10^{-7}$  mole of  $H_2SO_4$   
 (h)  $10^{-8}$  mole of  $Na_2SO_4$   
 (i)  $10^{-9}$  mole of  $Na_2CO_3$   
 (j)  $10^{-10}$  mole of  $NaOH$

Q.2. Calculate the number of molecules in 100 g of  $H_2O$ .  
 Q.3. Calculate the number of molecules in 100 g of  $CO_2$ .  
 Q.4. Calculate the number of molecules in 100 g of  $SO_2$ .  
 Q.5. Calculate the number of molecules in 100 g of  $SO_3$ .  
 Q.6. Calculate the number of molecules in 100 g of  $NaCl$ .  
 Q.7. Calculate the number of molecules in 100 g of  $CaCl_2$ .  
 Q.8. Calculate the number of molecules in 100 g of  $Na_2CO_3$ .  
 Q.9. Calculate the number of molecules in 100 g of  $NaOH$ .  
 Q.10. Calculate the number of molecules in 100 g of  $HCl$ .  
 Q.11. Calculate the number of molecules in 100 g of  $H_2SO_4$ .  
 Q.12. Calculate the number of molecules in 100 g of  $Na_2SO_4$ .

Q.13. Define the following terms:



# M/S 3 B BLACKBIO BIOTECH INDIA LIMITED

## Other Payables

### Advance from Customers

Particulars	Amount As at 31.03.2021
Sanbiomed	63,130.00
Pristine Bio Chemicals, Bhubaneshwar	16,636.62
Jeep Enterprises	11.20
Shayadri speciality labs	2.76
Scientific traders	2,24,000.00
<b>Total</b>	<b>3,03,780.58</b>





## 3 B BLACKBIO BIOTECH INDIA LIMITED

### Notes to the Financial Statements for the year ended 31st March 2021.

#### 1. Significant Accounting Policies

##### 1.1 Basis of Preparation

The financial statements have been prepared on the accrual basis and historical cost basis. There are certain financial assets and liabilities which are required to be measured at fair value amount. The financial statements of the Company have been prepared to comply with the Indian Accounting Standard ('Ind AS'), including the rules notified under relevant provisions Companies Act, 2013.

##### 1.2 Use of Estimates

The presentation of financial statements in conformity with generally accepted accounting principles requires the management to make estimates and assumption that affect the reported amounts of assets & liabilities, expenses and disclosure of contingent liabilities. Such estimates and assumption are based on the management's evaluation of relevant facts and circumstances as on the date of financial statements.

##### 1.3 Summary of Significant Accounting Policies

###### (a) Property, plant and equipment

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment loss. Costs directly attributable to acquisition are capitalized until the property, plant and equipment are ready for use, as intended by the Management. The Company depreciates property, plant and equipment over their estimated useful lives using the straight-line method. The estimated useful lives of assets are as follows:

Electrical Equipment's	10 years
Equipment's	5 Years
Furniture	10 Years
Computer(including computers used in R&D) <sup>(1)</sup>	3 Years
Lab Equipment's	10 Years
R&D Equipment's <sup>(1)</sup>	10 Years

<sup>(1)</sup>Based on technical evaluation, the Management believes that the useful lives as given above best represent the period over which the Management expects to use these assets. Hence, the useful lives for these assets is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013.

###### (b) Intangible Assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization and impairment loss, if any. Intangible assets comprising of Technology fees amortized over the period of 6 years.

###### (c) Inventories

Inventories are valued at Cost.

###### (d) Impairment of non-financial Assets-

Impairment is reviewed and recognized in the event changes and circumstances indicate that the carrying amount of any property, plant and equipment and intangible assets or group of assets, called cash generating units (CGU) is not recoverable. Difference between the carrying amounts and recoverable value shall be recognized as an impairment loss in the Statement of Profit & Loss.





**(e) Employee Benefits**

**Short Term Employee Benefits**

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by employees are recognized as an expense during the period when employees render the services.

**Post-Employment Benefits**

As per information provided to us no employees completed the specified period of service hence no provision is made for gratuity.

**(f) Tax Expenses**

Tax Expenses comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income tax Act, 1961 enacted in India and tax laws prevailing in respective tax jurisdiction where the company operates. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date.

Tax is recognized in the Statement of Profit and Loss, except to the extent that it relates to items recognized in the comprehensive income or in equity. In which case, the tax is also recognized in other comprehensive income or equity.

**(g) Foreign Currencies Transactions**

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction.

**(h) Revenue recognition**

Revenue is recognized on completion of Sales of goods or rendering services. Sale is exclusive of GST and packing and forwarding charges collected from customers.

**(i) Financial Instruments**

**Accounting policy**

**Initial recognition:**

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition, except for trade receivables which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are added to the fair value on initial recognition. Regular way purchase and sale of financial assets are accounted for at trade date.

**Subsequent measurement:**

**Non-derivative financial instruments**

(i) **Financial assets carried at amortized cost:** A financial asset is subsequently measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding

(ii) **Financial assets at fair value through other comprehensive income:** A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company has made an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income based on its business model.







(iii) **Financial assets at fair value through profit or loss:** A financial asset which is not classified in any of the above categories is subsequently fair valued through profit or loss.

(iv) **Financial liabilities:** Financial liabilities are subsequently carried at amortized cost using the effective interest method, except for contingent consideration recognized in a business combination which is subsequently measured at fair value through profit or loss. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

**Fair value of financial instruments:**

In determining the fair value of its financial instruments, the Company uses a variety of methods and assumptions that are based on market conditions and risks existing at each reporting date. The methods used to determine fair value include discounted cash flow analysis, available quoted market prices and dealer quotes. All methods of assessing fair value result in general approximation of value, and such value may never actually be realized.

**(j) Depreciation**

Depreciation on property, plant and equipment is provided using straight line method based on useful life of the assets prescribed in Schedule II to the Companies Act, 2013. The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively.

**(k) Contingent liability:** One Performance Bank Guarantee amounting to Rs 1,84,500/- ( against 100% margin in form of STDR ).

**(l)** Previous year figures have been regrouped and rearranged wherever necessary to meet current year presentational requirement.

**(m) Remuneration to Statutory Auditors**  
Fees for the Statutory Audit is Rs. 1.0 Lakh

**(p) Proposed Dividend:** The Company propose dividend Rs. 10/- per share, amounting to Rs. 1,02,75,000/- for financial year 2020-21.

**(q)** Interest income on bonds amounting to Rs. 55,56,972/- includes sum of Rs. 9,01,097/- being tax free in nature, details are as under:

Particulars	Amount(Rs)
National Highway authority Of India Bonds	2,44,179/-
Power Finance Corporation Ltd Non-Convertible Debentures	6,56,918/-
<b>Total</b>	<b>9,01,097/-</b>

**(r) Estimation of uncertainties relating to the global health pandemic from COVID-19 ("COVID-19"):** The Company has considered the possible effects that may result from the pandemic relating to COVID-19 in the preparation of these financial statements including the recoverability of carrying amounts of financial and non-financial assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company has, at the date of approval of these financial statements, used internal and external sources of information including credit reports and related information and economic forecasts and expects that the carrying amount of these assets will be recovered. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of these financial statements.





(s) **Related Party Disclosure:**

**Holding Company**

M/s Kilpest India Ltd.

M/s 2B Blackbio S.L. Spain

**Key Management Personnel and their relatives**

ShriDhirendraKuberDubey	- Managing Director
Shri Nikhil KuberDubey	- Whole Time Director
Smt. AnamikaDubey	- Wife of ShriDhirendraKuberDubey
Smt. MithilaDubey	- Wife of Late Shri-Ram KuberDubey
Master RaghavDubey	- Son ofDhirendraDubey
KumariRaginiDubey	- Daughter of Nikhil Dubey
Master RishabDubey	- Son ofDhirendraDubey

**Transaction with related parties:**

	Transactions (01/04/2020 31/03/2021)	to	Holding Company (Kilpest India Ltd.)	Associate Concerns (2B Blackbio S.L. Spain)	Key Management & Relatives	Viv Goobal Technologies (Prop. ShriPateekGoel)
1.	Premises Rent		6,20,256/-			
2.	Power & Electricity		9,90,000/-			
3.	Salary Expense		9,45,000/-		36,00,000/-	
4.	Travelling & Conference Exp.				54,870/-	
5.	License Fees and Other Fees		4,26,31,328/-			
6.	Commission on BG					
7.	Commission to Director				3,48,00,000/-	
8.	Sale of Goods		1,82,86,302/-			1,26,00,66,431/-
9.	Sale of Fixed Assets					11,50,000/-
10.	Packaging & Forwarding Charges Collected.					18,400/-
11.	Purchase of Goods					2,62,056/-
12.	Purchase of Fixed Assets					54,90,000/-
13.	Commission on sales					11,04,33,557/-
14.	Discount Allowed					25,20,000/-

(above transaction are exclusive of GST)


**(q) Additional Information:**

Particulars	2020-21	2019-20
a) Consumption of Raw Material	Rs. 41,66,94,278.68	Rs. 3,07,15,276.31
b) Value of Stores and Spares Parts.		
c) C.I.F. Value of Imported goods	Rs. 11,80,07,351.19	Rs 1,31,38,479.00
d) Remittance in foreign exchange	€ 7,14,068.47 \$ 7,51,619.27 £ 2,015.00	€ 39,411.04 \$ 1,49,633.97 £ 3,637.00 AED 1,000.00
e) Earning in foreign exchange	£ 17,726.30 In INR 16,81,930.00	€ 290.00 \$ 44,633.80 £ 25,490.80 In INR 55,58,235.00





## GLOBAL FOOTPRINT



**3B BlackBio Biotech India Ltd**

An ISO 13485:2016 Certified Company

7-C, Industrial Area, Govindpura, Bhopal-462023 (M.P.) INDIA Ph.: +91 98105 62700, +91755 4076518  
E: prateek@3bblackbio.com, info@3bblackbio.com, enquiry@3bblackbio.com W.: www.3bblackbio.com

Follow us at:



